Pivotal Year Ahead For Spain's PharmaMar
After Record Revenues In 2020
Executive Summary
The Madrid-based group's Aplidin is set to go back yet again to European regulators but the sea squirt-derived drug seems to be showing more potential in COVID-19 than in multiple myeloma.